Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab A/S    GMAB   DK0010272202


Real-time Estimate Quote. Real-time Estimate CHI-X - 07/14 10:59:45 am
2273 DKK   -2.74%
07/10GLAXOSMITHKLINE : FDA unclear if benefits of GSK multiple myeloma drug outweigh risks
07/08Genmab A/S - Major Shareholder Announcement
07/07Major Shareholder Announcement
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Genmab A/S : Grant of Restricted Stock Units and Warrants to Employees in Genmab

share with twitter share with LinkedIn share with facebook
06/03/2020 | 04:04pm EDT

Company Announcement

Copenhagen, Denmark; June 3, 2020 Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 4,982 restricted stock units and 15,645 warrants to employees of the company and three of the company's subsidiaries.

Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 1,948.

The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the board of directors in accordance with the Remuneration Policy adopted by the shareholders at the annual general meeting. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Stock information > Restricted stock units.

The exercise price for each warrant is DKK 1,948. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 620.64.

The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the board of directors on March 28, 2017. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Stock information > Warrants.

About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of three approved antibodies: DARZALEX® (daratumumab, under agreement with Janssen Biotech, Inc.) for the treatment of certain multiple myeloma indications in territories including the U.S., Europe and Japan, Arzerra® (ofatumumab, under agreement with Novartis AG), for the treatment of certain chronic lymphocytic leukemia indications in the U.S., Japan and certain other territories and TEPEZZA™ (teprotumumab, under agreement with Roche granting sublicense to Horizon Therapeutics plc) for the treatment of thyroid eye disease in the U.S. A subcutaneous formulation of daratumumab, DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), has been approved in the U.S. for the treatment of adult patients with certain multiple myeloma indications. Daratumumab is in clinical development by Janssen for the treatment of additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development by Novartis for the treatment of relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies, the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody® platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.

Marisol Peron, Corporate Vice President, Communications & Investor Relations
T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:
Andrew Carlsen, Senior Director, Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® and DARZALEX FASPRO™ are trademarks of Janssen Pharmaceutica NV. TEPEZZA™ is a trademark of Horizon Therapeutics plc.

Company Announcement no. 23
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V


  • 030620_CA23_Warrant Grant

© OMX, source OMX

share with twitter share with LinkedIn share with facebook
Latest news on GENMAB A/S
07/10GLAXOSMITHKLINE : FDA unclear if benefits of GSK multiple myeloma drug outweigh ..
07/08Genmab A/S - Major Shareholder Announcement
07/07Major Shareholder Announcement
07/06GENMAB A/S : - Major Shareholder Announcement
07/03Major Shareholder Announcement
07/02GENMAB A/S : has published its Articles of Association
06/30GENMAB A/S : Capital Increase in Genmab as a Result of Employee Warrant Exercise
06/29Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial o..
06/12GENMAB A/S : has published its Articles of Association
06/11ABBVIE : and Genmab Announce Broad Oncology Collaboration
More news
Sales 2020 9 539 M 1 454 M 1 454 M
Net income 2020 4 631 M 706 M 706 M
Net cash 2020 13 218 M 2 015 M 2 015 M
P/E ratio 2020 32,2x
Yield 2020 -
Capitalization 153 B 23 307 M 23 280 M
EV / Sales 2019
EV / Sales 2020 14,6x
Nbr of Employees 579
Free-Float 94,7%
Duration : Period :
Genmab A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 2 115,45 DKK
Last Close Price 2 337,00 DKK
Spread / Highest target 10,4%
Spread / Average Target -9,48%
Spread / Lowest Target -42,1%
EPS Revisions
Jan G. J. van de Winkel President & Chief Executive Officer
Deirdre P. Connelly Chairman
Anthony Mancini Chief Operating Officer & Executive Vice President
Anthony Pagano Chief Financial Officer & Executive Vice President
Michael K. Bauer SVP, Head-Operations, Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB A/S56.13%22 955
WUXI APPTEC CO., LTD.59.57%33 311
BIONTECH SE107.67%15 956